India’s indigenously-developed Covid vaccine Covaxin could quickly obtain Emergency Use Listing by the World Health Organisation, ultimately enabling its recipients to journey overseas with out obligatory quarantine, NITI Aayog’s Member, Health, VK Paul stated on Wednesday.
Data sharing and information analysis are happening and a positive resolution could come quickly, he stated.
“The information sharing and information analysis have been happening by means of a number of opinions and we’re near a call level.
“We must give time to WHO to make their decisions based on science. However, we hope that these decisions can be taken quickly because people who are receiving Covaxin have certain imperatives of travel. Most of us, who chose the concurrency, is important in terms of licensure. We are hoping for an early decision,” Dr Paul stated.
“We believe that a positive decision could be coming in, before the end of the month,” he added.
In August, Indian Health Minister Mansukh Mandaviya additionally met WHO Chief Scientist Dr Soumya Swaminathan and held discussions over the WHO approval of Covaxin.
The vaccine’s developer Bharat Biotech has submitted its Phase 3 medical trials information that demonstrated 77.8 per cent efficacy to the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
The WHO has thus far authorised Covid-19 vaccines by Pfizer-BioNTech, AstraZeneca, Johnson and Johnson, Moderna, and Sinopharm.